COMMUNIQUÉS West-GlobeNewswire

Alpha Pro Tech, Ltd. Announces Third Quarter 2025 Financial Results
05/11/2025
Overall Third Quarter Sales Increased 3.7% to $14.8 Million, Compared to $14.3 Million for the Third Quarter of 2024 Net sales for the third quarter of 2025 were $14.8 million, up 3.7% compared to $14.3 million for the [...]
CJ Biomaterials signs partnership with BIQ Materials to produce artificial turf infill made with PHACT™ PHA, a certified biodegradable biopolymer, for the European market
05/11/2025
CJ Biomaterials signed an agreement with BIQ Materials, a Swedish biomaterials compounding company, to accelerate the commercialization of PHACT™ PHA-based infill EU ban on intentionally added microplastics including [...]
HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes
05/11/2025
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade [...]
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
05/11/2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and [...]
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
05/11/2025
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments [...]
Mucinex Brings Mr. Mucus to Canada for the First Time With Proven 12-Hour Cold and Flu Relief
05/11/2025
The germ-loving, cult-favourite Mucinex mascot Mr. Mucus makes his Canadian debut in a coast-to-coast campaign challenging Canadians to kick this seasonal nuisance to the curb TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- [...]
Ambio Life Sciences Launches Europe’s First Physician-Led Ibogaine Clinic
05/11/2025
With the opening of its new clinic on Malta’s scenic Mellieha Bay, Ambio becomes the only transcontinental ibogaine provider in the world The clinic responds to high global demand for safe ibogaine treatment with added [...]
MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients
05/11/2025
First-of-its-kind study represents the potential for robotic-enabled microsurgical intervention for neurodegenerative diseases, including Alzheimer’s JACKSONVILLE, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MMI (Medical [...]
SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025
05/11/2025
DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc
05/11/2025
U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997 [...]
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
05/11/2025
New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic kidney disease Allschwil, Switzerland – [...]
beyond|AESTHETICS Celebrates 10 Years of Excellence with Grand Holiday Event
05/11/2025
Camarillo, CA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- beyond|AESTHETICS , a leader in the aesthetics industry, is thrilled to announce its 10 Year Anniversary Holiday Event, a spectacular celebration marking a decade of [...]
VALNEVA Declaration of shares and voting rights: October 31, 2025
05/11/2025
VALNEVA Declaration of shares and voting rights October 31, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
VALNEVA Déclaration d’actions et de droits de vote : 31 octobre 2025
05/11/2025
VALNEVA Déclaration d’actions et de droits de vote 31 octobre 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 [...]
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
05/11/2025
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week [...]
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
05/11/2025
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of [...]
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
05/11/2025
Webcast scheduled for Monday, November 10 at 12:00 pm EST REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on [...]
Crescent Biopharma to Present at November Investor Conferences
05/11/2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer [...]
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
05/11/2025
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]

Pages